FDA Cracks Down on Compounded GLP-1 drugs Marketed by Hims & Hers and Others
The U.S.Food and Drug Governance is taking aggressive action against companies marketing non-approved, compounded versions of popular GLP-1 drugs, citing concerns over safety, efficacy, and misleading advertising.
The FDA announced today, February 6, 2026, its intent to restrict the use of GLP-1 active pharmaceutical ingredients (APIs) in compounded drugs that are being mass-marketed as alternatives to FDA-approved medications. This move targets companies like Hims & Hers and other compounding pharmacies that have been offering these products directly to consumers. The agency’s primary concern is the inability to verify the quality, safety, or effectiveness of these unapproved drugs.
“We take seriously any potential violations of the Federal food, Drug, and Cosmetic Act,” stated martin A.Makary, M.D., M.P.H., commissioner of Food and Drugs. The FDA’s actions follow warning letters issued in the fall of 2025, addressing deceptive direct-to-consumer advertising and marketing practices.
the FDA is specifically prohibiting companies from claiming that their compounded products are generic versions or identical to FDA-approved drugs. furthermore, promotional materials cannot state that compounded drugs contain the same active ingredient or have been clinically proven to deliver results. The agency emphasized that these claims are false and misleading to consumers.
The FDA will utilize all available enforcement tools to address these issues, including potential seizure and injunction actions. Entities involved in the manufacture, distribution, or marketing of these unapproved compounded GLP-1 products have been warned that failure to comply may result in legal action without further notice.
The FDA, an agency within the U.S.Department of Health and Human Services, is responsible for protecting public health by ensuring the safety, effectiveness, and security of a wide range of products, including drugs, vaccines, medical devices, food, and cosmetics. This latest action underscores the agency’s commitment to safeguarding consumers from possibly harmful and unverified medications.
The agency’s move signals a heightened scrutiny of the rapidly growing market for compounded drugs and a determination to protect patients from unsubstantiated claims and potential health risks.
Why is the FDA taking action? The FDA is cracking down on companies mass-marketing compounded GLP-1 drugs due to serious concerns about patient safety and misleading claims. These compounded drugs haven’t undergone the rigorous testing and approval process required for FDA-approved medications, raising questions about their quality, purity, and effectiveness. The agency also found companies were falsely advertising these products as equivalent to established brands.
Who is affected? The primary targets of this action are companies like hims & Hers, as well as other compounding pharmacies directly selling these unapproved GLP-1 drugs to consumers. Ultimately, the action aims to protect all patients who might be tempted to use these potentially unsafe alternatives. The FDA sent warning letters in Fall 2025 to these companies.
What is the FDA doing? The FDA is prohibiting companies from falsely claiming their compounded drugs are generic versions or identical to FDA-approved medications. They are also banning claims that these drugs contain the same active ingredient or have proven clinical results. The agency is prepared to use its full enforcement powers, including seizures and injunctions, to ensure compliance.
How did it end? As of February 6, 2026, the FDA has issued its intent to restrict the use of
